Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786067 · ClinicalTrials.gov registry record · Phase 4
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
A Phase 4 study of Kidney Transplant Immunosuppression, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04786067 is a Phase 4 study of Kidney Transplant Immunosuppression that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04786067, a Phase 4 study of Kidney Transplant Immunosuppression, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune quiescence. The primary objective will be to determine if donor derived-cell free DNA (AlloSure) can be utilized to facilitate Belatacept monotherapy, and to determine if Belatacept is safe and effective as immunosuppression in kidney transplant recipients. The secondary objective is to determine the utility of AlloMap as a predictor of immune quiescence and tolerance of immunosuppressive de-escalation to Belatacept monotherapy, and to evaluate the performance of iBox in predicting adverse outcomes in patients transitioned to Belatacept monotherapy
Conditions Studied
Interventions
- DRUG Belatacept
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2025-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786067
The ClinicalTrials.gov registry entry for NCT04786067 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Immunosuppression appearing as the primary indexed condition, and to 1 intervention - of which Belatacept is the first listed.
NCT04786067 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04786067 about?
NCT04786067 is a clinical study titled "Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression". The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune quiescence. The primary objective will be to determine if donor derived-cell f...
What is the current status of trial NCT04786067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2021-07-28. Estimated completion is 2025-07-30.
What conditions does trial NCT04786067 study?
This clinical trial studies the following conditions: Kidney Transplant Immunosuppression.
What interventions are being tested in trial NCT04786067?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT04786067?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04786067 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.